HIF1A and neoplasm: Interestingly, the combination of lepatinib, receptor tyrosine kinase (RTK) inhibitor, and 2-deoxy-d-glucose (2-DG), a non-metabolizable glucose analog, decreased lactate and HIF1α expression, resulting in a decrease in cell viability, tumor growth inhibition, as well as in a decrease in angiogenesis, compared to the cytotoxic effects of both drugs alone.